PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Infliximab - Ankylosing spondylitis

PAD Profile : Infliximab - Ankylosing spondylitis

Keywords :
Biologic, anti-TNF, biosimilar, cytokine modulator, monoclonal antibody, TNF-alpha, axial spondyloarthritis, AS
Brand Names Include :
Remicade, Remsima, Inflectra, Flixabi, Zessly

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Intravenous infusion
  • Subcutaneous injection (sc)
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
06 December 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated axial spondyloarthritis pathway.

Treatment pathway is available on separate guidelines page.

06 January 2021
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee recommends the use of infliximab subcutaneous injection or infliximab intravenous infusion. Clinicians & patients will be able to choose the most appropriate product for them at the point of prescribing.

08 July 2019
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Medicines and Healthcare Products Regulatory Agency (MHRA) recommends to prescribe biological products by brand name to ensure that substitution of a biosimilar product does not occur when the medicine is dispensed by the pharmacist. Https://www/gov/uk/drug-safety-update/biosimilar-products

Primary care prescriber should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.

06 July 2016
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN agreed the attached Spondyloarthritis biologic treatment pathway in line with TA383 which was published by NICE in February 2016. The PCN previously (May 2015) supported the branded prescribing of biosimilar Infliximab(Inflectra OR Remsima) to be used in all new patients for all indications where they have licensing authorisation in the UK. Switching to Inflectra or Remsima has been discussed locally with acute trusts and specialists.

Associated BNF Codes

10. Musculoskeletal and Joint Diseases
10.01.03. Rheumatic disease suppressant drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More